Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07490639 | Family-Supported Palliative Care in Advanced Lung Cancer(FSPC-LC) | completed | N/A | 110 | Shanxi Province Cancer HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04960059 | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | completed | — | 24 | The Christie NHS Foundation TrustOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07475637 | Liquid Biopsy Monitoring Of EGFR T790M in Advanced Non-Small Cell Lung Cancer(LBM-T790M) | completed | — | 70 | Faculty of Medicine of TunisOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | completed | Phase 3 | 291 | NovoCure GmbHINDUSTRY | 18 | Mar 18, 2026 | clinicaltrials |
| NCT06328621 | Lung Cancer Risk Assessment and Etiology | completed | — | 109 | City of Hope Medical CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02504372 | Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)(PEARLS) | completed | Phase 3 | 1,177 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2026 | clinicaltrials |
| NCT02818920 | Neoadjuvant Pembrolizumab(TOP 1501) | completed | Phase 2 | 35 | Neal Ready MD PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04298606 | A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence | completed | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT01647867 | Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers(MetLung) | completed | N/A | 56 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02448758 | Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)(CB(NPC)²) | completed | — | 518 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06525246 | Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer | completed | Phase 1 | 78 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03313804 | Priming Immunotherapy in Advanced Disease With Radiation | completed | Phase 2 | 76 | John L. Villano, MD, PhDOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02402920 | Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer | completed | Phase 1 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06282991 | A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled | completed | — | 73 | PfizerINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07215026 | Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes(UNCOVER) | completed | — | 833 | AstraZenecaINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02858869 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | completed | Phase 1 | 25 | Emory UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04912687 | Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients(CIRCULAR) | completed | N/A | 581 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07432308 | Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC(Liquid biopsy) | completed | N/A | 22 | Institute of Oncology LjubljanaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT01279408 | Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC) | completed | — | 46 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03083041 | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 210 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04900363 | A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC | completed | Phase 1 / Phase 2 | 108 | AkesoINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02738398 | FDG PET/CT in Lung Cancer Staging | completed | N/A | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03564197 | 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC | completed | N/A | 80 | The Netherlands Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04894591 | To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)(SCLC) | completed | — | 272 | Jazz PharmaceuticalsINDUSTRY | 2 | Feb 27, 2026 | clinicaltrials |
| NCT03724331 | Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience | completed | N/A | 235 | University of NebraskaOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05263947 | Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation | completed | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02523469 | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 67 | Medical University of South CarolinaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07050472 | Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC) | completed | — | 45 | Anhui Shi, MDOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06575933 | A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04384146 | Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04312308 | A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients | completed | — | 100 | Yonsei UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04809103 | Intratumoral Cisplatin for Resectable NSCLC | completed | Phase 1 | 6 | University of VermontOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04184921 | Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients | completed | Phase 2 | 216 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05429320 | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04294810 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer(SKYSCRAPER-01) | completed | Phase 3 | 620 | Hoffmann-La RocheINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT06675695 | Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases | completed | — | 4,864 | Brigham and Women's HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04648033 | Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC(ARCADIAN) | completed | Phase 1 | 21 | University of OxfordOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04640480 | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | completed | Phase 1 | 21 | SN BioScienceINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT01897480 | A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations(Balise) | completed | Phase 2 | 168 | Eli Lilly and CompanyINDUSTRY | 9 | Jan 26, 2026 | clinicaltrials |
| NCT03003468 | Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 | completed | Phase 1 / Phase 2 | 35 | Lawrence Feldman, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03285321 | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 105 | Greg Durm, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 39 | Salma SabbourOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05001971 | Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy | completed | Phase 2 | 65 | Hunan Cancer HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT00596648 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 92 | ExelixisINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04452877 | A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | completed | Phase 2 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2026source: clinicaltrials